LOKV
Live Oak Acquisition Corp. V
$9.47
-4.44%
No data for this timeframe.
Vol
Price Targets
$13.25
+39.9% upside
Strong Buy
Current $9.47
Low $13.00
Median $13.25
High $13.50
2 analysts
$13.00
$13.50
Analyst Ratings
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Compass Point | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.08 | $-0.08 — $-0.08 | 1 | |
| Next Q | $-0.03 | $-0.03 — $-0.03 | 1 | |
| Current FY | $-19.51 | $-19.51 — $-19.51 | 1 | |
| Next FY | $-0.01 | $-0.03 — $0.02 | 100% YoY | 2 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Analyst Price Targets
$13.25 mean target
+39.9% upside
Strong Buy (1.50)
$13.00 Low
$13.50 High
| Metric | Value |
|---|---|
| Current Price | $9.47 |
| Target Low | $13.00 |
| Target Mean | $13.25 |
| Target Median | $13.25 |
| Target High | $13.50 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.08 | $-0.08 | $-0.08 | — | — | — | $0.1B | — | 1 |
| Next Q 2026-09-30 |
$-0.03 | $-0.03 | $-0.03 | — | — | — | $0.2B | — | 1 |
| Current FY 2026-12-31 |
$-19.51 | $-19.51 | $-19.51 | — | — | — | $0.7B | — | 1 |
| Next FY 2027-12-31 |
$-0.01 | $-0.03 | $0.02 | 100.0% | — | — | $1.1B | 74.2% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.080 | |
| 7d ago | $-0.540 | +0.460 |
| 30d ago | $0.000 | -0.080 |
| 60d ago | $0.000 | -0.080 |
| 90d ago | $0.000 | -0.080 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Compass Point | INITIATE | — | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.